erlotinib hydrochloride has been researched along with Dermatitis, Atopic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bass, SA; Gibson, AM; Khurana Hershey, GK; Xiao, C; Zhang, Z | 1 |
1 other study(ies) available for erlotinib hydrochloride and Dermatitis, Atopic
| Article | Year |
|---|---|
EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis.
Topics: Administration, Cutaneous; Allergens; Animals; Cells, Cultured; Chemokine CXCL1; Chemokine CXCL2; Dermatitis, Atopic; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation; Humans; Interleukin-17; Interleukin-1beta; Interleukin-22; Interleukin-6; Interleukins; Keratinocytes; Lymph Nodes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Mutant Strains; Quinazolines; Recurrence; Signal Transduction; Skin; Specific Pathogen-Free Organisms; Th17 Cells | 2014 |